291 related articles for article (PubMed ID: 28076322)
41. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.
Czekay RP; Aertgeerts K; Curriden SA; Loskutoff DJ
J Cell Biol; 2003 Mar; 160(5):781-91. PubMed ID: 12615913
[TBL] [Abstract][Full Text] [Related]
42. uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptors.
Montuori N; Cosimato V; Rinaldi L; Rea VE; Alfano D; Ragno P
Thromb Haemost; 2013 Feb; 109(2):309-18. PubMed ID: 23238745
[TBL] [Abstract][Full Text] [Related]
43. Deacetylated GM3 promotes uPAR-associated membrane molecular complex to activate p38 MAPK in metastatic melanoma.
Yan Q; Bach DQ; Gatla N; Sun P; Liu JW; Lu JY; Paller AS; Wang XQ
Mol Cancer Res; 2013 Jun; 11(6):665-75. PubMed ID: 23525268
[TBL] [Abstract][Full Text] [Related]
44. Progesterone receptor isoforms PRA and PRB differentially contribute to breast cancer cell migration through interaction with focal adhesion kinase complexes.
Bellance C; Khan JA; Meduri G; Guiochon-Mantel A; Lombès M; Loosfelt H
Mol Biol Cell; 2013 May; 24(9):1363-74. PubMed ID: 23485561
[TBL] [Abstract][Full Text] [Related]
45. TGF-β2 promotes RPE cell invasion into a collagen gel by mediating urokinase-type plasminogen activator (uPA) expression.
Sugioka K; Kodama A; Okada K; Iwata M; Yoshida K; Kusaka S; Matsumoto C; Kaji H; Shimomura Y
Exp Eye Res; 2013 Oct; 115():13-21. PubMed ID: 23810810
[TBL] [Abstract][Full Text] [Related]
46. Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors.
Mauro CD; Pesapane A; Formisano L; Rosa R; D'Amato V; Ciciola P; Servetto A; Marciano R; Orsini RC; Monteleone F; Zambrano N; Fontanini G; Servadio A; Pignataro G; Grumetto L; Lavecchia A; Bruzzese D; Iaccarino A; Troncone G; Veneziani BM; Montuori N; Placido S; Bianco R
Sci Rep; 2017 Aug; 7(1):9388. PubMed ID: 28839232
[TBL] [Abstract][Full Text] [Related]
47. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
48. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
49. Heregulin regulation of urokinase plasminogen activator and its receptor: human breast epithelial cell invasion.
Mazumdar A; Adam L; Boyd D; Kumar R
Cancer Res; 2001 Jan; 61(1):400-5. PubMed ID: 11196194
[TBL] [Abstract][Full Text] [Related]
50. siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells.
Subramanian R; Gondi CS; Lakka SS; Jutla A; Rao JS
Int J Oncol; 2006 Apr; 28(4):831-9. PubMed ID: 16525631
[TBL] [Abstract][Full Text] [Related]
51. Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide.
Gargiulo L; Longanesi-Cattani I; Bifulco K; Franco P; Raiola R; Campiglia P; Grieco P; Peluso G; Stoppelli MP; Carriero MV
J Biol Chem; 2005 Jul; 280(26):25225-32. PubMed ID: 15866865
[TBL] [Abstract][Full Text] [Related]
52. Cantharidin Impairs Cell Migration and Invasion of Human Lung Cancer NCI-H460 Cells via UPA and MAPK Signaling Pathways.
Hsia TC; Yu CC; Hsiao YT; Wu SH; Bau DT; Lu HF; Huang YP; Lin JG; Chang SJ; Chung JG
Anticancer Res; 2016 Nov; 36(11):5989-5997. PubMed ID: 27793925
[TBL] [Abstract][Full Text] [Related]
53. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling.
Aguirre Ghiso JA; Kovalski K; Ossowski L
J Cell Biol; 1999 Oct; 147(1):89-104. PubMed ID: 10508858
[TBL] [Abstract][Full Text] [Related]
54. Silencing profilin-1 inhibits gastric cancer progression via integrin β1/focal adhesion kinase pathway modulation.
Cheng YJ; Zhu ZX; Zhou JS; Hu ZQ; Zhang JP; Cai QP; Wang LH
World J Gastroenterol; 2015 Feb; 21(8):2323-35. PubMed ID: 25741138
[TBL] [Abstract][Full Text] [Related]
55. Urokinase-type plasminogen activator receptor (uPAR) ligation induces a raft-localized integrin signaling switch that mediates the hypermotile phenotype of fibrotic fibroblasts.
Grove LM; Southern BD; Jin TH; White KE; Paruchuri S; Harel E; Wei Y; Rahaman SO; Gladson CL; Ding Q; Craik CS; Chapman HA; Olman MA
J Biol Chem; 2014 May; 289(18):12791-804. PubMed ID: 24644284
[TBL] [Abstract][Full Text] [Related]
56. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
Festuccia C; Angelucci A; Gravina GL; Biordi L; Millimaggi D; Muzi P; Vicentini C; Bologna M
Thromb Haemost; 2005 May; 93(5):964-75. PubMed ID: 15886816
[TBL] [Abstract][Full Text] [Related]
57. Cadmium induces urokinase-type plasminogen activator receptor expression and the cell invasiveness of human gastric cancer cells via the ERK-1/2, NF-κB, and AP-1 signaling pathways.
Khoi PN; Xia Y; Lian S; Kim HD; Kim DH; Joo YE; Chay KO; Kim KK; Jung YD
Int J Oncol; 2014 Oct; 45(4):1760-8. PubMed ID: 25069788
[TBL] [Abstract][Full Text] [Related]
58. HMGB1 induces human non-small cell lung cancer cell motility by activating integrin αvβ3/FAK through TLR4/NF-κB signaling pathway.
Zhu J; Luo J; Li Y; Jia M; Wang Y; Huang Y; Ke S
Biochem Biophys Res Commun; 2016 Nov; 480(4):522-527. PubMed ID: 27769864
[TBL] [Abstract][Full Text] [Related]
59. Involvement of ERK1/2 and p38 MAP kinase in doxorubicin-induced uPA expression in human RC-K8 lymphoma and NCI-H69 small cell lung carcinoma cells.
Niiya M; Niiya K; Shibakura M; Asaumi N; Yoshida C; Shinagawa K; Teshima T; Ishimaru F; Ikeda K; Tanimoto M
Oncology; 2004; 67(3-4):310-9. PubMed ID: 15557793
[TBL] [Abstract][Full Text] [Related]
60. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
